ECKERT+ZIEGLERINH O.N. overview

EQS-News: Eckert & Ziegler SE / Key word(s): Alliance/Agreement Eckert & Ziegler Enters Strategic Partnership with Bicycle Therapeutics for Radioisotope Supply and Contract Development and Manufacturing of Bicycle Radio Conjugates 27.02.2025 / 15:00 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, Germany, 27 February 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX), a leading provider of isotope technology for medical, scientific, and industrial use,...

EQS-News: Eckert & Ziegler SE / Key word(s): Miscellaneous Eckert & Ziegler Ensures Business Continuity After Cyber-Attack 25.02.2025 / 09:59 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, 25 February 2025. Following a cyber-attack on the IT infrastructure of Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) at the beginning of February, the Group's business operations can continue in most areas. In a few cases, there are still restrictions due to the...

EQS-Ad-hoc: Eckert & Ziegler SE / Key word(s): Miscellaneous Eckert & Ziegler Affected by Cyber Attack 13-Feb-2025 / 09:21 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Berlin, 13 February 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) has suffered a cyber attack on parts of its IT systems. The systems were...

EQS-News: Eckert & Ziegler SE / Key word(s): Miscellaneous Eckert & Ziegler SE: IT Incident Affects Eckert & Ziegler SE's Communication Channels 03.02.2025 / 13:23 CET/CEST The issuer is solely responsible for the content of this announcement. Press Release IT Incident Affects Eckert & Ziegler SE's Communication Channels Berlin, 03 February 2025. Due to an unexpected IT incident, Eckert & Ziegler is currently unable to receive emails or phone calls. We understand the inconvenience this may cause...

EQS-Ad-hoc: Eckert & Ziegler SE / Key word(s): Preliminary Results Eckert & Ziegler Announces Preliminary Figures for 2024: Significant Increase in Sales and Adjusted EBIT 27-Jan-2025 / 18:55 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Financial Year 2024 (preliminary): Sales of around EUR 295 million (previous year:...

EQS-Ad-hoc: Eckert & Ziegler SE / Key word(s): Alliance Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture 14-Jan-2025 / 17:03 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Berlin, 14 January 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) today signed a licence agreement with Qi...

EQS-News: Eckert & Ziegler SE / Key word(s): Alliance/Incoming Orders Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement 13.01.2025 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, Germany and Sydney, Australia, 13. January 2025. Eckert & Ziegler (ISIN DE0005659700, SDAX) and GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company specialising in developing antibody radiopharmaceuticals for solid...

EQS-News: Eckert & Ziegler SE / Key word(s): Regulatory Admission/Market Launch Eckert & Ziegler Submits GalliaPharm® for Approval by Japan’s Health Authority MHLW 13.12.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, 13 December 2024. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, announces the submission of its GalliaPharm® 68 Ge/...